Lupin acquires brands in VMS and CNSLUPIN - 1171 Change: 38.20 (3.37 %)
News: Lupin’s board has approved the acquisition of a portfolio of brands of Anglo-French Drugs & Industries and its associates to strengthen Lupin’s portfolio in vitamins, minerals and supplements and CNS segments. The acquisition is for a lumpsum consideration of Rs.325 crore and the turnover of the brands being acquired for FY21 was Rs.94.6 crore.
Views: Lupin’s acquisition of Anglo French Drug’s portfolio brands is an astute move to seek additional levers of growth in therapies like VMS and CNS. According to IQVIA MAT December 2021, CNS and VMNS group contributed 4.3% and 3.8%, respectively, to Lupin’s India business. Overall, therapy-wise VMNS and CNS has grown at CAGR of 12.3% and 10.3%, respectively, in the last four years in India (IQVIA, MAT December 2021). Lupin’s acquisition of brands to expand in VMS and CNS could provide an additional leg of growth for domestic business, going forward, from FY23.